Soft tissue sarcoma is a type of cancerous tumor that forms in the body’s soft tissues, such as muscle, fat, fibrous tissue, and blood vessels. If it occurs in the shoulder, it might feel like a ...

Efficacy of combination of immune checkpoint inhibitors, chemotherapy, and targeted therapy in advanced/refractory cancer. A phase Ib/II study of pacritinib, an interleukin 1 receptor associated ...

Anlotinib combined with chemotherapy showed a 30.8% ORR and 82.7% DCR in advanced STS patients, indicating promising efficacy. The study involved 52 patients with high-grade STS, with a median ...

Patients with non-metastatic soft tissue sarcoma (STS) who need pre-operative radiation therapy can safely receive hypofractionated treatment over three weeks instead of five, with comparable tumor ...

Soft tissue sarcomas are rare—only about 13,500 cases are diagnosed in the United States each year. They arise from what are called mesenchymal cells, which form the connective tissues in the body, ...

In patients with mostly undifferentiated pleomorphic sarcomas, 2-year DFS with the addition of preoperative and postoperative pembrolizumab (Keytruda) infusions reached 67%, as compared with 52% with ...

This article first appeared with Targeted Oncology ™. An orphan drug designation (ODD) was granted by the FDA to elraglusib for the treatment of patients with soft tissue sarcoma (STS). 1 Currently, a ...

One expert from the University of Colorado Cancer Center explains the multidisciplinary aspect of sarcoma care to maximize patients’ functioning. Treating patients with soft tissue sarcoma or bone ...

Iovance Biotherapeutics reported early clinical trial data for lifileucel in advanced soft tissue sarcomas, showing promising efficacy signals. The company also received FDA Fast Track designation for ...

Iovance Biotherapeutics IOVA shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarcomas. This ...

Iovance Biotherapeutics shares rose after the company shared positive trial results from a treatment designed for soft tissue cancer. The stock gained 26% to $3.65 Tuesday. Shares are still down 32% ...